• WNT5a/GSK3/β-Catenin Control of FAP Adipogenesis

  2026-08-27

  The reference study identifies the WNT5a/GSK3/β-catenin axis as a central regulator of adipogenic differentiation in skeletal-muscle fibro/adipogenic progenitors. By combining pharmacological perturbation, high-dimensional cytometry, transcriptomic integration, network modeling, and mouse injury models, it connects suppression of GSK3 with reduced fatty degeneration and improved muscle-supportive FAP activity.

• Necrostatin-1: A Translational RIP1 Strategy

  2026-08-27

  A thought-leadership framework for using Necrostatin-1 as a causal probe of RIP1 kinase signaling, linking necroptosis assays with inflammatory lung disease, tissue injury, and acute kidney injury research.

• FPS-ZM1: Translating RAGE Biology from Metabolism to AD

  2026-08-26

  A translational framework for using FPS-ZM1 to test how RAGE links hypothalamic metabolic stress, amyloid beta signaling, blood-brain barrier transport, and neuroinflammation—while keeping preclinical evidence and clinical expectations distinct.

• AP20187: Turning Dimerization into Translation

  2026-08-26

  AP20187 is a chemical inducer of dimerization that converts engineered protein proximity into controllable signaling. This thought-leadership guide connects its mechanism and validation profile with translational design lessons from chronic intermittent hypoxia research.

• Phosphatase Inhibitor Cocktail: Preserve Signal

  2026-08-25

  Learn how the Phosphatase Inhibitor Cocktail (2 Tubes, 100X) supports protein phosphorylation preservation across lysate workflows. This article adds a decision framework linking phosphatase control to the APEX2–TERT study and orthogonal assay interpretation.

• Protease Inhibitor Cocktail (MS-SAFE, 50X in DMSO)

  2026-08-25

  Protease Inhibitor Cocktail (MS-SAFE, 50X in DMSO) helps limit endogenous proteolysis during cell and tissue protein extraction, including workflows prepared for mass spectrometry. It is not a complete substitute for metalloproteinase or phosphatase control; add and validate EDTA or dedicated inhibitors separately when those activities are relevant.

• Antipyrine in BBB Permeability Research

  2026-08-24

  Antipyrine combines high water compatibility with a well-defined analytical profile, making it a practical comparator for BBB transport, pharmacokinetic studies, and drug metabolism research. This guide shows how to integrate it into LLC-PK1-MOCK/MDR1 assays while separating passive permeability from efflux and lysosomal-trapping artifacts.

• GRA12 Revealed by In Vivo CRISPR Screening

  2026-08-23

  A pooled in vivo CRISPR-Cas9 study identifies the dense-granule protein GRA12 as a conserved Toxoplasma gondii virulence factor across parasite strains and mouse backgrounds. Functional validation links GRA12 to parasitophorous-vacuole stability and protection from immune-associated host-cell necrosis, establishing a framework for studying broadly conserved host–parasite mechanisms.

• BKT140: A CXCR4 Assay Decision Framework

  2026-08-22

  BKT140 and BL-8040 provide a functional way to interrogate CXCR4 signaling across cancer migration, apoptosis, and stem cell mobilization. This article translates recent CXCR4 theranostic findings into endpoint-specific assay design and interpretation strategies.

• Prednisone Workflows for PBL Apoptosis Research

  2026-08-21

  Prednisone provides a practical way to model G1-phase arrest, IL-2 pathway suppression, and lymphocyte apoptosis in controlled cell-based experiments. This guide connects PBL assays with chemical-stability checks, neurodegeneration models, and troubleshooting strategies for more reproducible results.

• Machine-Learning Discovery of Senolytics

  2026-08-20

  The reference study presents a cost-efficient machine-learning workflow that uses published screening data to identify senolytic candidates without requiring a large new proprietary dataset. Computational screening followed by testing in human cell models identified ginkgetin, periplocin, and oleandrin as active compounds, while also illustrating how heterogeneous literature data can accelerate early-stage drug discovery.

• Senescent CAFs Drive Breast Cancer Progression

  2026-08-20

  Ye et al. identify senescent myofibroblast cancer-associated fibroblasts as a tumor-promoting stromal population that suppresses natural killer cell cytotoxicity through extracellular matrix remodeling. Genetic or pharmacologic depletion of these senescent CAFs restored antitumor immunity in mice, while their presence in human breast lesions was associated with recurrence risk.

• PARP1–FAK–COL5A1 Signaling in Ovarian Cancer

  2026-08-19

  The reference study identifies a cholesterol-responsive PARP1/FAK/COL5A1 signaling axis that promotes epithelial–mesenchymal transition and tumorigenesis in ovarian cancer cells adapted to persistent cholesterol exposure. Its combination of long-term conditioning, molecular perturbation, and in vitro and in vivo analyses provides a framework for studying how metabolic stress reshapes FAK-dependent cancer progression.

• Necrostatin-1: RIP1 Kinase Inhibitor Guide

  2026-08-19

  Necrostatin-1 is a selective allosteric RIP1 kinase inhibitor used to interrogate necroptosis and tissue-injury signaling. The product dossier reports activity in TNF-α-induced necroptosis assays and mouse liver and kidney injury models, while emphasizing that assay-specific validation remains necessary.

• Mannosylated LNPs for In Vivo mRNA Delivery

  2026-08-18

  The reference study introduces cholesterol-derived mannopolypeptides as an integrated targeting component for lipid nanoparticles, rather than relying on post-formulation antibody modification. Its CPSM-LNP and CM/CPSM-LNP systems improved dendritic-cell transfection and showed preferential lymph-node accumulation in mice, providing a preclinical framework for more targeted mRNA delivery.

442 records 6/30 page Previous Next First page 上5页 678910 下5页 Last page